Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Lukas H. Haaksma, Raffaele Palmieri, Jesse M. Tettero, Tom Reuvekamp, Lok Lam Ngai, Costa Bachas, Angèle Kelder, Willemijn J. Scholten, Patrycja Gradowska, Valentina Arena, Anderson Simione, Luca Maurillo, Adriano Venditti, Bob Lowenberg, Gert J. Ossenkoppele, David C. de Leeuw, Maura R. V. Ikoma-Colturato, Francesco Buccisano, Jacqueline Cloos

Blood (2024) 144 (Supplement 1): 4329.

https://doi.org/10.1182/blood-2024-203158

Published: 2024

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Alfonso Piciocchi, Valentina Arena, Monica Messina, Sonia Maria Orlando, Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Paola Fazi, Marco Vignetti, Francesco Buccisano, Adriano Venditti

Blood (2022) 140 (Supplement 1): 3192–3193.

https://doi.org/10.1182/blood-2022-158942

Published: 2022

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2021-147200

Published: 2021

Journal Articles

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Raffaele Palmieri, MD, Alfonso Piciocchi, Valentina Arena, MS, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Maria Irno Consalvo, Consuelo Conti, Cristina Attrotto, Daniela Fraboni, Maria Teresa Voso, MD, William Arcese, MD PhD, Adriano Venditti, MD, Francesco Buccisano, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139557

Published: 2020

Journal Articles

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139773

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Blood (2019) 134 (Supplement_1): 5083.

https://doi.org/10.1182/blood-2019-129184

Published: 2019

Journal Articles

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD, Raffaele Palmieri, MD, Maria Irno Consalvo, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria Del Principe, Valentina Arena, Stefano Soddu, Ambra Di Veroli, MD, Giovangiacinto Paterno, Eleonora De Bellis, Daniela Fraboni, Consuelo Conti, Maria Teresa Voso, MD, William Arcese, Adriano Venditti

Blood (2019) 134 (Supplement_1): 2688.

https://doi.org/10.1182/blood-2019-128025

Published: 2019

NARROW

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only